Phaseline

Companies › LEO Pharma

LEO Pharma: clinical trials, targets and expected readouts

3 active drug programs in 8 registered trials: 4 Phase 2, 3 Phase 3, 1 Phase 4; Immunology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Spesolimab
IL36 receptor antagonist
IL36R, IL1RAPPhase 4Generalized Pustular Psoriasis; Pyoderma GangrenosumSep 2027
Delgocitinib
Janus Kinase (JAK) inhibitor
JAK3, JAK1, JAK2, TYK2Phase 3Lichen Sclerosus; Palmoplantar Pustulosis; Central Centrifugal Cicatricial Alopecia; VitiligoDec 2026
Tralokinumab
Interleukin-13 inhibitor
IL13Phase 3Atopic DermatitisApr 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06013969SpesolimabPhase 4Generalized Pustular PsoriasisImmunologyMay 2026
NCT07013201DelgocitinibPhase 2Palmoplantar PustulosisImmunologyDec 2026
NCT07487948DelgocitinibPhase 2Central Centrifugal Cicatricial AlopeciaImmunologyApr 2027
NCT07820098DelgocitinibPhase 2VitiligoImmunologyApr 2027
NCT03886246SpesolimabPhase 2Generalized Pustular PsoriasisImmunologySep 2027
NCT06624670SpesolimabPhase 3Pyoderma GangrenosumImmunologyNov 2027
NCT07335588DelgocitinibPhase 3Lichen SclerosusImmunologyMar 2028
NCT06311682TralokinumabPhase 3Atopic DermatitisImmunologyApr 2028

Targets

JAK3 (1) JAK1 (1) JAK2 (1) TYK2 (1) IL36R (1) IL1RAP (1) IL13 (1)

Companies with the same targets

AbbVie Incyte Pfizer Sun Pharmaceutical Industries Alfasigma Takeda Eisai Suzhou Zelgen Biopharmaceuticals Chia Tai Tianqing Pharmaceutical Group Chengdu Zenitar Biomedical Technology

Companies built like this

Alfasigma Galderma R&D Sun Pharma Japan Integrative Skin Science and Research Alumis

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.